Abstracts tagged "pain management and treatment options"

Abstract Number: 2222 • 2016 ACR/ARHP Annual Meeting
Tai Chi Is More Effective Than Aerobic Exercise in Treating Fibromyalgia: A Randomized Controlled Trial
Chenchen Wang¹, Christopher Schmid², Roger A. Fielding³, William F. Harvey¹, Lori Lyn Price⁴, Jeffrey B. Driban¹, Kieran Reid³, Robert A. Kalish⁵, Ramel Rones⁶ and Timothy E. McAlindon⁷, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Brown University School of Public Health, Providence, RI, ³Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, ⁴Clinical Care Research, Tufts Medical Center, Boston, MA, ⁵Div of Rheumatology, Tufts Medical Center, Boston, MA, ⁶Center for Mind–Body Therapies, Boston, MA, ⁷Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Fibromyalgia is a complex disorder with strong psychological and pain components and is best managed with multidisciplinary therapies. Previous studies have suggested that Tai…
Abstract Number: 2046 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Efficacy In Acute Pain: Results From Two Phase 3 Studies
Roy D. Altman¹, Allan Gibofsky², Mark Jaros³ and Clarence Young⁴, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³Summit Analytical, Denver, CO, ⁴Iroko Pharmaceuticals, Philadelphia, PA
Background/Purpose: Indomethacin is used to treat acute gouty arthritis and other acute pain conditions but, like other NSAIDs, is associated with dose-related gastrointestinal, cardiovascular, and…
Abstract Number: 2047 • 2013 ACR/ARHP Annual Meeting
Lower-Dose Indomethacin Submicron Particle Capsules’ Combined Safety From Two Phase 3 Studies In Patients With Acute Pain Following Elective Surgery
Allan Gibofsky¹, Roy D. Altman², Clarence Young³, Daniel Solorio⁴ and Jennifer Nezzer⁵, ¹Medicine and Public Health, Hospital for Special Surgery, New York, NY, ²David Geffen School of Medicine, UCLA, Los Angeles, CA, ³Iroko Pharmaceuticals, Philadelphia, PA, ⁴Iroko Pharmaceuticals, LLC, Philadelphia, PA, ⁵Premier Research, Philadelphia, PA
Background/Purpose: Indomethacin is prescribed to treat acute pain and inflammation but, like other NSAIDs, is associated with dose-dependent gastrointestinal, cardiovascular, and renal adverse events (AEs).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].